Highlights Quoin Pharmaceuticals, Ltd.

Equities

QNRX

US74907L4095

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 18:56:40 11/03/2026 GMT			5-day change	1st Jan Change
8.610 ^USD	+0.26%		+1.29%	-40.33%

06:06pm	Quoin Pharmaceuticals Ltd. Announces FDA Grants Fast Track Designation For QRX003 For The Treatment Of Netherton Syndrome	CI
01-27	Quoin Pharmaceuticals Announces Submission to Japanese MHLW for Orphan Drug Designation for QRX003 in Netherton Syndrome	CI

Highlights

06:06pm	Quoin Pharmaceuticals Ltd. Announces FDA Grants Fast Track Designation For QRX003 For The Treatment Of Netherton Syndrome	CI
01-27	Quoin Pharmaceuticals Announces Submission to Japanese MHLW for Orphan Drug Designation for QRX003 in Netherton Syndrome	CI
01-20	Quoin, Inc. Announces Application for Breakthrough Medicine Designation with the SFDA for QRX003	CI
11-11	Quoin Pharmaceuticals Announces Achievement of Topical Rapamycin Target Loadings for Two Proprietary Delivery Technologies	CI
11-06	Quoin Pharmaceuticals, Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
28/10/25	Quoin Pharmaceuticals Ltd. Announces Recruitment of Three Additional Patients in Investigator Pediatric Netherton Syndrome Study and Provides Positive 9 Month 'Whole Body' Data Update from Ongoing Study	CI
21/10/25	Quoin Pharmaceuticals announces U.S. FDA grants orphan drug designation for QRX003 in Netherton Syndrome	RE
07/08/25	Quoin Pharmaceuticals, Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
26/06/25	Quoin Pharmaceuticals Ltd. Releases New Netherton Now Video Featuring Professor Mellerio, International Expert in Genetic Skin Diseases	CI
24/06/25	Quoin Pharmaceuticals Ltd. Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Netherton Syndrome	CI
24/06/25	Certain Warrants of Quoin Pharmaceuticals, Ltd. are subject to a Lock-Up Agreement Ending on 24-JUN-2025.	CI
22/05/25	Quoin Pharmaceuticals Ltd. Announces FDA Clearance to Initiate Second Pivotal Whole Body Qrx003 Netherton Syndrome Clinical Study	CI
22/05/25	Quoin Pharmaceuticals Says US FDA Clears Second Netherton Syndrome Pivotal Study	MT
14/05/25	Quoin Pharmaceuticals Announces Initial Positive Clinical Data for QRX003 from Pediatric Peeling Skin Syndrome Study	CI
13/05/25	Quoin Pharmaceuticals, Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
30/04/25	Quoin Pharmaceuticals Regains Compliance With Nasdaq	RE
02/04/25	Quoin Pharmaceuticals Ltd. Announces Additional Positive 'Whole Body' Clinical Data from Ongoing Pediatric Netherton Syndrome Study and Approval to Initiate Testing of A Second Pediatric Patient	CI
25/03/25	Quoin Pharmaceuticals Files U.S. Patent Application for Novel Topical Formulations to Treat Netherton Syndrome and Other Skin Diseases	CI
13/03/25	Quoin Pharmaceuticals, Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
04/03/25	Quoin Pharmaceuticals Files U.S. and International Patent Applications for Novel Topical Rapamycin Formulations to Treat Rare Disease Indications	CI
27/02/25	Quoin Pharmaceuticals Ltd. Announces Highly Positive 'Whole Body' Clinical Data from Ongoing Pediatric Netherton Syndrome Study	CI
23/01/25	Quoin Pharmaceuticals Ltd. Announces Further Clinical Evidence of QRX003 Effectiveness in Netherton Syndrome	CI
16/01/25	Quoin Pharmaceuticals Ltd. Announces Positive Clinical Data from its Ongoing Pediatric Netherton Syndrome Study	CI
06/01/25	Quoin Pharmaceuticals Ltd. Announces Additional Positive Interim Data from Ongoing Open-Label Netherton Syndrome Clinical Study	CI
20/12/24	Quoin Pharmaceuticals Prices $6.8 Million Equity Offering -- Shares Fall	MT